The Questions Patients Ask When a Pill Won’t Cooperate
Medication adherence is less about willpower than friction—and patients feel that friction online. Every day, people with chronic conditions go […]
AI Can Rewrite Your Story: The New Corporate Communications Problem
In April 2026, Sullivan & Cromwell — one of the most prestigious law firms on Wall Street — apologized to
What Happens When Investors Ask AI About Your Company? For Biopharma, the Answer Is Often Wrong, Outdated, or Missing Entirely
An investor researching a biopharmaceutical company in 2026 is more likely to open ChatGPT, Perplexity, or Gemini than to read
The Untracked Layer of Pharma Competitive Intelligence: What People Actually Ask AI
The short answer: Most pharma competitive intelligence still runs on search rankings, social listening, and claims data. None of that
What If Your Competitive Intelligence Started With What People Actually Ask?
Fifty-one percent of US adults now say they use an AI chatbot such as ChatGPT, Gemini, or Copilot, up from
Profound, Peec, and Scrunch Can Tell You AI Mentioned Your Drug. None of Them Can Tell You If the Mention Was Legal.
Six tools now dominate the market for tracking how brands show up in ChatGPT, Perplexity, Gemini, and Google’s AI Overviews:
General
Argus Finds Adverse Events. AI Monitoring Finds Bad Answers. They’re Not the Same Job.
On March 11, 2026, the FDA retired the FDA Adverse Event Reporting System, the database that has anchored US drug
The label says one thing, the patient hears another: the small print that quietly rewrites therapy
There is a particular kind of failure mode in medicine that doesn’t look dramatic from the outside. No needles in
Off-Label Revenue Is Real Revenue. It’s Also Fragile Revenue.
In April 2018, the Department of Justice intervened in five whistleblower lawsuits against Insys Therapeutics, alleging the company had built
The Call Before the Call: What AI Monitoring Tells Field Sales Teams Before the Rep Walks In
About two-thirds of practicing US physicians, roughly 650,000 people, now use a chatbot called OpenEvidence to help decide how to
Off-Label Use Can Boost Sales. It Can Also Break Forecasts.
The Short Answer In November 2013, Johnson & Johnson agreed to pay more than $2.2 billion to resolve criminal and
How to Evaluate an AI Brand Monitoring Vendor: A Buyer’s Checklist for Medical Affairs
The short answer: An AI brand monitoring RFP for a pharma organization needs to test a vendor on eight things:
